| Document |
Document Title |
|
WO/2022/150899A1 |
The present invention relates to the field of diagnostic medicine, vaccinology and biotechnology. More specifically, the present invention relates to a chimeric protein for use in diagnosing visceral leishmaniasis in humans and dogs, inc...
|
|
WO/2022/152186A1 |
Provided is a fully human single-domain tandem chimeric antigen receptor (CAR) capable of specifically binding to a CD5 protein, which CAR contains a CD5 binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellul...
|
|
WO/2022/151958A1 |
Provided are a human CD276-targeting monoclonal antibody and an application thereof. Specifically, provided are a CD276-targeting antibody, which has a high affinity and a high specificity for human CD276. Further provided are a pharmace...
|
|
WO/2022/154127A1 |
The present invention provides a desired antibody or antibody composition by modifying a thiol group chemically introduced into an antibody. More specifically, the present invention provides an antibody composition, etc., having desired ...
|
|
WO/2022/152308A1 |
Provided herein is an engineered dimeric antibody comprising in each monomer a Fab domain specifically binding to a Trop2 antigen operably linked to an engineered hinge region, wherein the engineered hinge region is composed of a portion...
|
|
WO/2022/155503A1 |
Provided herein are multispecific antigen binding proteins that selectively bind a particular KKLC-1 (CT-83) shared antigen and CD3, as well as related methods, kits, and compositions. Included herein are multispecific antigen binding pr...
|
|
WO/2022/151959A1 |
The present invention provides a CAR-T cell targeting B7-H3 and an application thereof in the treatment of acute myeloid leukemia (AML). Specifically, the present invention provides a CAR-T cell targeting B7-H3, which comprises an scFv w...
|
|
WO/2022/153698A1 |
The purpose of the present invention is to provide a chimeric target factor receptor which can activate an antigen presenting cell, e.g., a dendritic cell, in a target-factor-specific manner. A chimeric target factor receptor is provided...
|
|
WO/2022/151746A1 |
A fusion enzyme and the use thereof in a paper-based biosensor. A GDH-linker-CBM fusion enzyme constructed by a flavin adenine dinucleotide (FAD)-dependent glucose dehydrogenase (GDH) gene and a carbohydrate binding module (CBM) gene, wh...
|
|
WO/2022/154547A1 |
Disclosed is a switching peptide applicable to a multiplex immunoassay method. The switching peptide comprises: a peptide compound capable of reversibly binding to a binding antibody; and a mass label substance bound to the peptide compo...
|
|
WO/2022/150878A1 |
Peptides that each bind to a receptor of a reproductive cell (including a follicle stimulating hormone receptor, a luteinizing hormone receptor, or an Anti-Mullerian hormone receptor) are described herein. In addition, nanoparticle const...
|
|
WO/2022/155258A1 |
Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and...
|
|
WO/2022/154548A1 |
Disclosed is a switching peptide that can be applied to an optical one-step immunoassay method. The switching peptide comprises: a peptide compound capable of reversibly binding to a binding antibody; and a fluorescent marker bound to th...
|
|
WO/2022/149934A1 |
The present invention relates to an antibody-polyethylene glycol-photosensitizer conjugate for anticancer immunotherapy of cancer cells in which a specific receptor is overexpressed. The conjugate improves the cancer cell targeting abili...
|
|
WO/2022/148255A1 |
Provided is a chimeric antigen receptor (CAR) for activating dendritic cells (DCs) in an immunosuppressive tumor environment. Compositions comprising the CAR, polynucleotides encoding the CAR, vectors comprising polynucleotides encoding ...
|
|
WO/2022/149609A1 |
The present invention addresses the problem of establishing a means for providing a component vaccine that can achieve both of the induction of cellular immunity mainly associated with MHC class I and the induction of humoral immunity as...
|
|
WO/2022/148491A1 |
Disclosed are a method and application for testing the concept of biological substances such as proteins, peptides, viruses, and microorganisms or biological small molecular substances by linking a single-domain antibody or a scFv or Fab...
|
|
WO/2022/150792A1 |
The present invention uses an indinavir based mechanism of "chemically induced dimerization" to enable a precise temporal control of the activity of a T cell engaging complex in a patient.
|
|
WO/2022/149568A1 |
The present invention relates to a CRISPR-dCas (dead Cas) protein having a helix region, being capable of forming a complex with guide RNA and target RNA, and having no nuclease activity, or a CRISPR-Cas protein having nuclease activity,...
|
|
WO/2022/142978A1 |
The present invention relates to the field of biomedicine. Provided is the use of HrpW-type multi-mimotope ligandins in food products, cosmetics, health products or pharmaceuticals. The HrpW-type multi-mimotope ligandins comprise HrpWPsd...
|
|
WO/2022/143611A1 |
Provided is a BCMA-targeting single-domain antibody, which has high affinity for a BCMA protein. Further provided is the use of the single-domain antibody in the preparation of a medicament for preventing or treating a disease or condition.
|
|
WO/2022/143999A1 |
Provided in the present invention is an aqueous formulation containing a dimer of two single-stranded gp130-Fc fusion proteins, and histidine salt, trehalose and polysorbate 80. The aqueous formulation can be used to treat inflammatory d...
|
|
WO/2022/142524A1 |
The present invention relates to a human papillomavirus type 31 chimeric protein and a use thereof. Specifically, the present invention relates to a human papillomavirus chimeric protein, containing or being composed of an HPV31 L1 prote...
|
|
WO/2022/143515A1 |
The present application provides a human GLP-1 polypeptide variant. A fusion protein or an immunoconjugate constructed by using the human GLP-1 polypeptide variant can be used for preventing and/or treating GLP-1 related metabolic diseas...
|
|
WO/2022/143870A1 |
Disclosed is an antibody that specifically binds to BCMA. The antibody comprises a heavy chain variable domain VH, a light chain variable domain VL, and a chimeric antigen receptor that contains the sequence thereof. Further disclosed ar...
|
|
WO/2022/142523A1 |
The present invention relates to a human papillomavirus type 18 chimeric protein and the use thereof. Specifically, the present invention relates to a papillomavirus chimeric protein, which comprises or consists of an HPV type 18 L1 prot...
|
|
WO/2022/141378A1 |
The present invention relates to the technical field of biotechnologies, and in particular, to an anti-PD-1 single-domain antibody. The present invention provides an anti-PD-1 single-domain antibody. Complementarity determining regions (...
|
|
WO/2022/141771A1 |
Provided is a long-acting IL-15 fusion protein, comprising a monomer fragment Fc, an IL-15 receptor α "Sushi" domain, and an IL-15 functional fragment. The IL-15 fusion protein has a higher yield than a Fc fusion protein, and can reduce...
|
|
WO/2022/142272A1 |
The present invention provides a CLDN18.2 antibody and an application thereof. Specifically, the present invention also describes a nucleic acid encoding the antibody, a composition comprising the antibody, a method for preparing the ant...
|
|
WO/2022/143951A1 |
Provided is an antibody binding to CD70, or antigen-binding portion thereof, comprising heavy chain CDRs selected from the group consisting of amino acid sequences SEQ ID NOs: 5, 6, 7, 15, 16, 22, 29, 30, 31, 37, 38, 44, 45, 46, 54, 55, ...
|
|
WO/2022/142525A1 |
Provided are an HPV chimeric protein and a use thereof. The HPV chimeric protein of the present invention comprises an HPV58 L1 protein or a mutant thereof and a polypeptide derived from a HPV16 L2 protein and inserted into a surface reg...
|
|
WO/2022/143516A1 |
Provided in the present application is a human GLP-1 polypeptide variant, and a fusion protein or an immunoconjugate constructed by means of using the human GLP-1 polypeptide variant can be used for preventing and/or treating metabolic d...
|
|
WO/2022/147298A1 |
The present disclosure relates generally to recombinant antibodies that bind to and activate human vascular-endothelial cadherin (VE-cadherin), as well as methods of their use, for instance, in activating cell adhesion of a cell layer in...
|
|
WO/2022/139071A1 |
The present invention relates to an intracellular delivery technique for delivering a biologically active material into cells and, more particularly, to a novel cell-penetrating peptide having excellent cell penetrating ability and a use...
|
|
WO/2022/135441A1 |
Provided are a complex of an anti-IL-4R antibody or an antigen-binding fragment thereof, and a medical use thereof. Specifically, provided are a complex of an antibody that specifically binds to IL-4R or an antigen-binding fragment there...
|
|
WO/2022/133592A1 |
Stabilized TCR constructs comprising a TCR alpha chain polypeptide having a variable alpha (Vα) domain and a constant alpha (Cα) domain and a TCR beta chain polypeptide having a variable beta (Vβ) domain and a constant beta (Cβ) doma...
|
|
WO/2022/140150A1 |
The present disclosure provides improved genome editing compositions and methods for editing a double-strand DNA target site. The disclosure further provides genome edited cells produced by the compositions and methods described.
|
|
WO/2022/138984A1 |
The present invention provides a neurite outgrowth promoter for promoting neurite growth on nerve cells of a postnatal mammalian individual for use in a condition in which an effective amount of a glial cell-derived neurotrophic factor (...
|
|
WO/2022/134487A1 |
A fusion protein of a polypeptide and a Helicobacter pylori ferritin, and a subunit vaccine for preventing novel coronavirus (SARS-CoV-2) infection prepared by using the fusion protein. The polypeptide comprises one or more S1 proteins o...
|
|
WO/2022/134047A1 |
Provided is inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, provided are methods of treating a complement-mediated disease or complement-mediated disorder in an individual by cont...
|
|
WO/2022/140706A1 |
The disclosure details methods for producing peptide-based vaccines for immunizing mammalian subjects against the SARS Coronavirus SARS-CoV-2, and additionally describes peptide vaccines and methods for immunizing mammalian subjects, inc...
|
|
WO/2022/135231A1 |
Provided are a recombinant protein, a protein complex containing the recombinant protein, and an application. The recombinant protein is composed of a human interleukin 1 receptor antagonist protein and a protein containing a VPGKG repea...
|
|
WO/2022/135563A1 |
Provided is a method for simultaneously inducing an immune response against multiple viruses (such as influenza viruses and novel coronavirus). Provided is an immunogenic peptide including: (a) an immunogenic stem including an HA2 region...
|
|
WO/2022/139070A1 |
The present invention relates to an intracellular delivery technology for delivering biologically active substances into cells and, more specifically, to a novel cell-penetrating peptide having an excellent cell-penetrating ability, and ...
|
|
WO/2022/138692A1 |
The present invention provides an antigen-binding molecule (e.g. antibody) with improved cytosol-penetrating ability, the molecule comprising an amino acid substitutions on at least one selected from the group consisting of CDRL1, CDRL2 ...
|
|
WO/2022/133329A1 |
Autoregulatory systems that have been implemented to control the expression and activity of Cast 3d, including the activity of Cast 3d in vivo, thereby reducing collateral damage in cells at off-target sites (e.g., non-target messenger R...
|
|
WO/2022/126689A1 |
Provided are an anti-B7H3 chimeric antigen receptor and an application thereof. The anti-B7H3 chimeric antigen receptor comprises an antigen binding domain, a hinge region, a transmembrane domain and a signaling transfer structural domai...
|
|
WO/2022/127372A1 |
Provided in the present application is a chimeric antigen receptor, including a GPC3 antigen binding domain, an ICD1, ICD2 or ICD3 intracellular signal stimulation domain with amino acid sequences of SEQ ID NOs: 29, 31 and 33, respective...
|
|
WO/2022/126416A1 |
An anti-BCMA antibody or an antigen-binding fragment thereof, and an application thereof in the treatment or prevention of tumor.
|
|
WO/2022/127401A1 |
Provided in the present invention is a single-chain antibody scFv that specifically binds to CD123, including an amino acid sequence selected from SEQ ID NOs: 56, 57, 58, 59, 60 and 61. Also provided is a chimeric antigen receptor target...
|
